Maxim Group Cuts Indaptus Therapeutics (NASDAQ:INDP) Price Target to $5.00

Indaptus Therapeutics (NASDAQ:INDP) had its target price dropped by stock analysts at Maxim Group from $8.00 to $5.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price objective indicates a potential upside of 329.18% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Indaptus Therapeutics in a research note on Wednesday, October 16th.

Indaptus Therapeutics Trading Up 1.3 %

NASDAQ INDP traded up $0.02 during trading on Wednesday, reaching $1.17. The company’s stock had a trading volume of 8,507 shares, compared to its average volume of 63,868. The firm has a 50 day moving average price of $1.33 and a 200 day moving average price of $1.84. Indaptus Therapeutics has a 12 month low of $1.03 and a 12 month high of $3.10. The firm has a market capitalization of $11.88 million, a price-to-earnings ratio of -0.68 and a beta of 1.45.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. On average, equities analysts forecast that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.